Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) EBITDA (2020 - 2025)

Historic EBITDA for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$1.5 million.

  • Journey Medical's EBITDA rose 4716.66% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 6949.76%. This contributed to the annual value of -$13.7 million for FY2024, which is 55976.85% down from last year.
  • According to the latest figures from Q3 2025, Journey Medical's EBITDA is -$1.5 million, which was up 4716.66% from -$2.9 million recorded in Q2 2025.
  • In the past 5 years, Journey Medical's EBITDA ranged from a high of $17.2 million in Q3 2023 and a low of -$13.8 million during Q2 2021
  • Its 5-year average for EBITDA is -$4.5 million, with a median of -$3.3 million in 2025.
  • Per our database at Business Quant, Journey Medical's EBITDA crashed by 539121.34% in 2021 and then skyrocketed by 28167.93% in 2023.
  • Over the past 5 years, Journey Medical's EBITDA (Quarter) stood at -$9.1 million in 2021, then dropped by 10.36% to -$10.0 million in 2022, then surged by 78.95% to -$2.1 million in 2023, then soared by 206.18% to $2.2 million in 2024, then crashed by 168.44% to -$1.5 million in 2025.
  • Its last three reported values are -$1.5 million in Q3 2025, -$2.9 million for Q2 2025, and -$3.3 million during Q1 2025.